T
HE LITERATURE related to growth factors increases at such a rapid rate that the cynical might postulate factors governing the development of new growth factors. In an effort to put a manageable perimeter around the subject, this review focuses primary attention on well characterized growth factors, known or suspected to exist in man.
While a universally accepted definition of a growth factor does not exist, usage accepts growth factors as relatively small proteins that induce increased cell synthesis of nucleic acids, protein, and increased cellular mass. Conventionally, growth factors are considered to be agents with mitogenic activity. However, in connective tissues where a disproportionately small number of cells participate in the formation of a large extracellular matrix, growth may be manifested not only by increased cell numbers, but also by increases in one or several components of the extracellular matrix. The physiologic import of this distinction is not trivial when one recalls that approximately 75% of the human body is of mesenchymal origin, and that skeletal tissues, skin, and fascia (excluding muscular components) account for >33% of the body mass.'** Also, it is pertinent to note that one of the first known growth factors, sulfation factor, was measured by its growth promoting activity as judged by the increased sulfated glycosaminoglycan (GAG) content of cartilage extracellular matrix. Sulfation factor was subsequently shown to be several proteins constituting a group of human growth hormone dependent proteins, members of the somatomedin family; knowledge of their mitogenic properties was a later development.
The same principle applies to epithelial tissues; for example, epidermal growth factor (EGF) stimulates not only replication of cells, but formation of extracellular material such as keratin. Similarly, connective tissue cells exposed to EGF respond with both increased cell replication and increased synthesis and secretion of hyaluronic acid, an extracellular matrix component.
Although the notion of growth promotion evokes the impression that growth factors are primarily concerned with anabolic events, it may be wise to visualize growth as a net increment in cells and certain of their extracellular products. Some growth factors also promote events whose primary impact is catabolic; connective tissue activating peptide-(CTAP-III), primarily known for its mitogenic and GAG stimulating properties, also stimulates synthesis and secretion of a degradative protease, plasminogen activator.3 Similarly, interleukin-1 (Il-1). a potent stimulator of anabolic processes, also promotes synthesis and secretion of collagenase and prostaglandins by many types of sensitive cells. It seems likely that some growth factors evoke both anabolic and catabolic behavior by a single cell. The mechanism(s) for organized integration of these opposing metabolic vectors in intact organisms will be a focus of investigative effort in the future.
Earlier debate aimed at classifying growth factors as hormones or autacoids now seems moot in the face of new data and the recognition of the depth of our ignorance. For instance, it seems likely that the several growth factors released from platelet alpha granules after platelet aggregation exert a potent local effect, thus behaving as autacoid mediators. Yet, there are no data to rule out significant distant (hormonal) biological effects from these substances, at least some of which are found in plasma. In the case of Alternatively, the availability of the purified growth factor may allow preparation of a radiolabeled conjugate so that it may be detected and measured in membrane receptor assays. Immunologic methods, however, may fail to distinguish between active and inactive forms of a particular molecule, in addition to possible problems related to cross reactivity; radioreceptor assays may also on occasion give rise to nonspecific results.
WELL DEFINED HUMAN GROWTH FACTORS
A partial list of well defined growth factors that may have biological importance in humans is shown in Table 1 . 
EGF-Urogastrone
EGF was first described in the mouse submaxillary gland and later isolated from human urine (as urogastrone).6 Computer based studies indicate that the precursor of mouse EGF (mEGF) has substantial similarity to bovine factor X, data supporting the concept that EGF arose early in vertebrate species.' New evidence localizing an EGF-like material in the human platelet alpha granule argues that it may be synthesized by megakaryocytes in humans.* Aspects of the discovery, isolation, and mechanism of action of EGF have been summarized.g*'O EGF from mouse submaxillary gland and human urine is a heat stable acidic polypeptide chain; it has been sequenced and shown to have 53 amino acid residues and three intramolecular disulfide bonds. Synthesized and stored in the submandibular gland, mEGF is found in granular form in convoluted tubules.
In vivo, EGF stimulates cell proliferation, keratinization, premature eruption of incisors and inhibits gastric acid secretion. Merino sheep, infused with EGF, showed temporary cessation of follicular activity, and wool protein became abnormal."
Palatogenesis during embryonic development may be controlled in part by EGF; the presumed mechanism involves increased concentration of environmental hyaluronic acid, thought to be critical for palatal shelf elevation and/or fusion of medial epithelium."
In vitro actions of EGF-urogastrone include stimulation of cell proliferation in many types of epithelial and fibroblastic cells. EGF induces increased synthesis of DNA, RNA, cyclic nucleotides, and enhanced transport of nutritional precursors. In appropriate cell types, EGF stimulates synthesis and secretion of specialized proteins (as prolactin or collagen) and complex carbohydrates (as hyaluronic acid). EGF induced stimulation of prolactin synthesis in rat pituitary celis apparently depends on accelerated transcription of the prolactin gene.13 Although mEGF caused selective dose dependent synthesis of collagen fibers by rat liver epithelial cells,14 it had little effect on collagen formation in cultures of rat liver fibroblasts" and reduced collagen synthesis in mouse osteoblastic cultures.'6 Such data emphasize and ambiguities in growth factor bioassays that may result from the choice of species or tissue type used to serve as a target system.
Binding of EGF to specific fibroblast receptors is irreversible; it is followed by phosphorylation of the receptors, internalization, and proteolytic processing in lysosomes. Remodeled receptor fragments may serve as intracellular signals for the multiple specific actions attributed to EGF." The gene coding for the human EGF receptor is believed to reside on chromosome No. 7." Peptides derived from the receptor protein show a high degree of homology with the deduced sequence of the v-erb-B transforming protein of the avian erythroblastosis virus." Retrovirus transformed rat fibroblasts have been shown to synthesize and secrete a transforming growth factor type I (rTGF-I, also, rTGFcu) that shows substantial sequence homology with the mEGFurogastrone family and shares the same biological activities.20 TGF-& said to be present in normal cells and stored in platelets, is unrelated to EGF structurally or functionally, but regulates the number of receptors for EGF in certain cell types." Monoclonal antibodies against the EGF receptor protein induce some of the effects of EGF itself, including stimulation of thymidine incorporation into DNA. This observation supports the concept that information in the EGFmembrane receptor system resides primarily in the membrane receptor itself. 22 Recently, a chemically synthesized gene for hEGF was expressed in yeast; the resultant biosynthetic hEGF was shown to compete with "'1-mEGF in a receptor binding assay using human dermal fibroblast plasma membranes23 and was reported to elicit precocious eyelid opening, incisor eruption, and inhibition of gastric secretion. Although this study yielded small quantities of hEGF, the methodology has potential for providing large enough amounts of this protein to permit full exploration of its many possible biological and medical applications. For instance, topically applied EGF has been reported to promote healing of cornea1 ulcers.24
Physiologic control of EGF as well as the pathophysiologic roles of this peptide are yet dimly lit arenas. In the mouse, EGF is known to be regulated by androgens; recent evidence indicates that thyroid hormones and adrenocortical hormones also regulate EGF in this species.2' In senescent mice, the submandibular glands appar-ently contain decreased amounts of EGF.26 Binding sites for EGF in skin fibroblasts from patients with neurofibromatosis were greatly diminished compared with age and passage matched normal strains."
Platelet Factors
It is clear that human platelets contain both cationic and anionic growth factors; one laboratory reported three different forms.2s Current interest centers on four classes of growth promoting proteins, cationic proteins such as connective tissue activating peptide-(CTAP-III) and the several molecular forms of platelet derived growth factors (PDGF), and anionic platelet derived growth factors including CTAP-P, and possibly EGF.
Connective Tissue Activating Peptide-III
This thrombin releasable growth promoting factor in human platelets has been isolated and studied in detai1.29,30 CTAP-III, isolated from both fresh and outdated human platelets, is a 9,278-dalton single chain protein with an average isoelectric point of 8.5.3' Recent data show isoelectric point related microheterogeneity that modifies growth factor activity.
Amino acid sequence and immunologic studies demonstrate that CTAP-III differs from fl-thromboglobulin (fi-TG) by an additional amino terminal tetrapeptide.3'"2 Proteolytic removal of the amino terminal tetrapeptide degrades CTAP-III to fl-TG and obliterates growth factor activity. Growth factor activity, as measured by enhanced DNA or GAG synthesis in human fibroblast cultures, also depends on the intact status of one or both of the two intrachain disulfide bonds. 
Platelet Derived Growth Factor(s) (PDGF)
Preparations have been interpreted to suggest that PDGF is a molecule with two disulfide linked chains, each with a molecular weight of 14,000 to 16,000 daltons3* PDGF is generally believed to exist in two forms: PDGF-I and PDGF-II whose molecular weights are 3 1,000 and 28,000 daltons, respectively.39 Differences in glycosylation lead some to postulate four molecular forms of PDGF.40 Preliminary sequence studies of PDGF show no resemblance to CTAP-II1. 4 EGF must be considered as a possible platelet derived anionic growth factor on the basis of radioimmunoassay and radioreceptor assay data; it appears to be located in the platelet alpha granules and is released during blood coagulation." In addition to the human platelet derived growth factors, recent reports suggest that human platelets contain an endothelial cell growth factor49 and a transforming growth factor (TGF)." The relationship of platelet EGF to platelet TGF is unclear. Further purification and characterization of these materials will determine whether they are distinct from the better defined platelet derived factors. Thus, it appears that platelets may carry two anionic (EGF and CTAP-P2) and two cationic (CTAP-III and PDGF) thrombin extrudable factors that are immunologically and structurally distinct. It is not known whether they are derived from a common larger protein or whether they are synthesized as completely separate entities.
Insulin-Like Growth Factors (ZGA, Z, ZZ) and Somatomedins
Radioimmunoassay methods that specifically recognized insulin demonstrated that only 7% of the insulin-like activity of serum was insulin (and consequently suppressible by antiinsulin serum); the remainder was originally designated as nonsuppressible insulin-like activity (NSILA). The NSILA material(s) are themselves growth hormone dependent, and in turn have growth promoting activity in chick embryo fibroblast cultures and in several other systems. NSILA has now been resolved into two entities: insulin-like growth factors I and II (IGF-I, IGF-II) whose covalent structures are known.51 IGF-I is a single chain containing 70 residues (7,649 daltons) with three disulfide bonds; it exhibits marked homology with proinsulin.51V52 IGF-II is a 7,471 dalton protein with three intrachain disulfide bonds, and it shows substantial homology with both IGF-I and proinsulin.
Both IGF-I and IGF-II stimulate DNA synthesis in chick embryonic tissue and 35S04 uptake in rat costal cartilage;53 both IGF species also promote mitosis in rabbit lens epithelial cells.54 In skeletal muscle, fat, and heart cells, IGF stimulated 2-deoxyglucose (2-dG) uptake, presumably not acting through the insulin receptor. Although IGF was 50 to 100 times more potent than insulin with respect to growth parameters, it was only l/60 as potent as insulin in stimulating 2-dG uptake by fat cells."
Radioimmunoassay and radioreceptor assays suggested that IGF-I was related to somatomedin C (SM-C);S6 recent amino acid sequence analysis of purified SM-C now confirms the identity of SM-C and IGF-I." Skin fibroblasts were shown by radioimmunoassay to secrete material resembling SM-C; secretion was blocked by cycloheximide and stimulated by hGH (human growth hormone), platelet derived growth factors and fibroblast growth factor (FGF), but not by EGF, thyroxine, or cortisol." Parenteral injection of ovine growth hormone into hypophysectomized rats resulted in increased tissue extractable IGF-1 /SM-C from kidney, heart, liver, lung, and testes; these data support the concept of multiple sites of synthesis coupled with a local site of action.59
Radioimmunoassay of IGF-I and IGF-II show IGF-I levels to be elevated in acromegaly and depressed in hGH deficiency. Enhanced secretion of IGF-II with acromegaly is not seen; however, the values are low in hGH deficiency, supporting the belief that both factors are growth hormone dependent. Extra pancreatic tumors associated with hypoglycemia were not associated with increased levels of IGF-I and IGF-IL60 Leprechaunism, a syndrome characterized by growth retardation, poor muscle development, and absence of fat, may result from deficiency of insulin-like growth factor activity. Some patients with this syndrome were reported deficient in cellular receptors for IGF-L6' The demonstration that synthetic IGF-l/SM-C has biological and immunologic properties identical to the natural product should facilitate the testing of these materials in relevant clinical contexts.62
Growth hormone affects cartilage by inducing the formation of secondary substances, soma-tomedins (formerly, sulfation factors), which in turn interact with chondrocytes to modify their metabolism.
Somatomedins in serum stimulate 3sS0, uptake by cartilage from hypophysectomized rats; serum from hypophysectomized rats is less stimulatory than that from normal rats, and administration of growth hormone restored stimulatory activity to the serum of hypophysectomized animals. 63 Bioassay of somatomedins in human serum disclosed high activity levels in acromegaly; lower levels were found after hypophysectomy and in patients with pituitary dwarfism. hGF injected into hypophysectomized patients or pituitary dwarfs restores human somatomedin levels to the normal range.
At least three somatomedins (A, B, and C) were thought to be present in human plasma; somatomedin A (SM-A) isolated from human plasma has a molecular weight of approximately 7,000 with asparagine at its N-terminus.
SM-A stimulates incorporation of 'SO, into GAG in chick cartilage and DNA synthesis in both chick embryo and human fibroblasts.64 Somatomedin B (SM-B) stimulated DNA synthesis in human glial cells and human embryonic lung fibroblasts.'j5 Purification of SM-C from human plasma led to proof that it is identical to IGF-I. Although IGF-I and IGF-II bind to multiplication stimulation activity (MSA) receptors, it may not mean that IGF and MSA are identical; the data may suggest multiple types of receptors for IGF materials.66 One review characterized MSA as a rat plasma somatomedin that shares properties with IGF-I, IGF-II, and insulin.67
Interleukin 1
IL-l, the first well defined human monokine, was originally known as lymphocyte activating factor (LAF). It is a potent mitogen for mouse thymocytes and may be an important mediator of inflammation in humans, possibly also acting as an endogenous pyrogen.68V69 IL-1 is secreted by activated macrophages of human and mouse and by large granular human lymphocytes.70 Synthesis of IL-1 may also be triggered by a cell contact dependent process involving activated lymphocytes, and promoted by endotoxins and phagocytosis. IL-1 stimulates helper T cell release of IL-2, a T cell growth factor. IL-1 not only has a role in promoting T cell proliferation, but it modifies in vitro immune responses and induces incremental PGEz and collagenase synthesis and secretion by human synovial cells.7'~73 Both the murine and human form of IL-1 have been purified to near homogeneity;68.74 human IL-1 is heat labile and stable to acid and thiols, and has a molecular weight of 11,000 to 15,000 daltons with an isoelectric point near 7.1.
In addition to the many immunologically oriented activities of IL-1, recent studies indicate that this peptide stimulates DNA synthesis in normal human connective tissue cells and promotes formation of major extracellular matrix components, including collagen and glycosaminoglycans. Its high specific activity makes this molecule a candidate for major roles in the inflammatory process.
Connective Tissue Activating Peptide-Urine (CTAP-U)
CTAP-U is a 16 to 30 kilodalton peptide isolated from human urine75 that stimulates DNA, hyaluronate, and sulfated GAG formation in skin, synovial, and cartilage fibroblast cultures. Proteolytic digestion destroys its growth factor activity, but biological activity is unaffected by thiol, acid, or heat treatment. Both ion exchange chromatography and preparative isoelectric focusing define two major areas of activity in the ranges of pH 2 to 3 and pH 4 to 5. Whether this represents two or more different growth factors or microheterogeneity of one agonist is unclear. CTAP-U does not compete in radioreceptor assays with insulin, basic somatomedin, or EGF and is immunologically distinct from CTAP-III, CTAP-P,, IgG, and its Fc and Fab fragments. Little is known about the origin of this peptide( It could represent urinary tract associated autacoid(s) or metabolite(s) of growth or nongrowth factor protein(s).
CTAP-PMN
A human granulocyte derived factor that stimulates DNA and GAG synthesis by human fibroblasts, CTAP-PMN is relatively heat stable, sensitive to thiols, and has a molecular weight between 12,700 and 15,700 daltons. This factor might play a role in chronic proliferative synovitis or in other settings where exudative inflam-mation is accompanied by connective tissue growth.76
Nerve Growth Factor (NGF)
Although present in many tissues, NGF is found in high concentrations in some snake venoms and in the male mouse submaxillary gland." It elicits overgrowth of sympathetic chain ganglia in vivo and promotes halo-like outgrowth of nerve fibers from embryonic sympathetic ganglia cultured in vitro. NGF may be important in regulation of neural cell growth and differentiation and may contribute to the survival of peripheral sympathetic and spinal sensory neurons.
NGF isolated from the mouse submaxillary gland is a hexameric 140,000 dalton protein complex composed of a, @, and y subunits. The LX subunit subserves a regulatory function, the y subunit is an arginine esteropeptidase, and the biological activity resides in the p subunit. 78 The /3 subunit of NGF (/3NGF) has been sequenced; the primary peptide has a molecular weight of 13,259 daltons and associates in two subunits with a molecular weight of 26,518 daltons. @NGF has three disulfide bonds, and the many acidic residues present in the amide form may account for its basic nature. The biological activity of PNGF is inhibited in the hexameric complex; this in turn protects the active component from proteolysis.
Administration of antibodies to NGF to animals causes total destruction of the sympathetic nervous system. NGF may be viewed as a hormone capable of positive pleiotropic stimulation of developing nerve tissue, and may be required in small amounts to maintain a mature sympathetic nervous system. NGF activity immunologically identical to that of submaxillary glands has been found in blood and other peripheral organs. Structural similarities between NGF and proinsulin lead to the suggestion that NGF is related in an evolutionary sense to a primitive form of proinsulin.
There are few unambiguous data confirming the presence of NGF in human tissues. A recent review emphasizes the possible role of nerve growth factor in human neoplasms including sarcoma, neuroblastoma, and gliomas." Older data suggested that NGF was secreted by a human glioblastoma cell strain.*' Further, human melanoma cells in culture were shown by indirect immunofluorescence to possess surface NGF; NGF receptors were thought to be present on the basis of both immunofluorescence and "'1-NGF binding. *2 A highly purified receptor for NGF has also been prepared from membranes of a human melanoma cell line by affinity chromatography. 83 The similarity of physiologic deficits in Alzheimer disease and some functions subserved by NGF led to speculation that this malady may be caused either by a deficiency of NGF or decreased responsiveness of cholinergic neurons to NGF. 84 Other lines of evidence indicate that NGF is chemotactic for human leukocytes in vitro at concentrations similar to those that stimulate neurite outgrowth,*' suggesting that this peptide may normally modulate nonneural cell function, possibly playing a role in wound repair.
GROWTH FACTORS AND NEOPLASIA
The fundamental observation that tumor cells conserve the transformed phenotype and that neoplastic transformation may be the result of genetic alteration has important consequences, among others, the ability of malignant cells to produce growth factors capable of lowering or replacing their serum requirements during propagation in vitro. 86 The concept of neoplastic transformation is being expanded by study of retroviruses, whose presence is thought to be required to initiate and maintain viral transformations7 The viral transforming agents, termed oncogenes, are recognized in vertebrate cellular genes (c-one)** and can be actively transcribed. 89 It is believed that they were integrated into the viral genome during vertebrate infection,W and because these protooncogenes are closely conserved during evolution, it is supposed that their normal function is related to the regulation of cell replication and/ or differentiation."
One of the acute transforming retroviruses of primate origin is the simian sarcoma virus (SSV).9' Its genome arose by recombination of simian associated virus with a segment derived from a woolly monkey cellular gene (v-sis).92 The entire genomic nucleotide sequence has been reported,93 the transforming gene product has been identified (p28""),9' and the human homologue (c-sis) has been localized in chromosome 22,94 with 93% nucleotide sequence homology between c-sis and v-sis.95,94
Recently, two different laboratories42.43 independently concluded that a segment of the predicted amino acid sequence of ~28"" has identical structural homology (87.1%) with the known amino terminal amino acid sequence of one of the PDGF chains.42,95 Subsequently, it was found that lysates of SSV transformed NIH-3T3 cells contain a growth factor that is identical to PDGF in immunoassay and has a mitogenic activity that is absent in nontransformed control cell lysates. This PDGF-like material has a different molecular weight (20,000 daltons) in SDS gels after immunoprecipitation with anti-PDGF antiserum; it is supposed that this represents the degraded product of ~28"'*.~' These findings raise interesting questions in view of the fact that ~20"'" is not secreted9' and that PDGF by itself does not induce neoplastic transformation.98
A recent report" indicated that the predicted v-erb-B transforming protein amino acid sequence closely resembles the partially known sequence of the transmembrane and the cytoplasmic kinase domains of EGF receptor. Interestingly, it appears that the avian erythroblastosis virus carries in its genome the encoding sequences of an abnormal EGF receptor that lacks its binding region, perhaps leading to constant generation of a signal similar to that produced by EGF, with subsequent rapid and autonomous cell proliferation.'9*99 There is evidence that other growth factor receptors besides EGF, including PDGF, insulin, and IGF-I have tyrosine kinase activity, along with the recognition that other encoded oncogene products (such as pp60'"'C, P9OWYe", P85gag-fes) have this kind of enzymatic activity.'@I Some are structurally related to the bovine CAMP dependent protein kinase catalytic chain,"' providing further support for the notion that transformation might occur as a result of alteration(s) at multiple points along the mitogenic pathway. It is possible, then, that more than one signal is needed to induce oncogenic cell behavior. Perhaps several oncogenes act in concert and the action of one controls another, enhancing, inducing, or alter- How does one explain so many factors with many overlapping functions? Are some of in vivo importance and others bioassay artifacts? Is something gained by their acting in concert, in different combinations or sequences? A partial list of types of information that would help to resolve these questions is shown in Fig 1. Sensitive specific immunologic methods permitting sequential measurement of concentrations and locations of multiple factors during the course of well defined pathologic processes would help put these agents into a realistic perspective. The powerful impact of growth factors and the oncogene concept on thinking about the pathogenesis of neoplasia may have an important counterpart in relation to the chronic inflammatory process, which is also characterized by self perpetuation, abnormal cell function, proliferation, and tissue destruction.
COMMENTS
The preceding sections have alluded to possible roles for various growth factors in normal growth and differentiation, and in the pathogenesis of acute and chronic inflammation, atherosclerosis, wound healing, neoplasia, and certain degenerative diseases. We may expect that the short term future will see the application of quantitative immunoassay and receptor assay techniques to the diagnosis and management of such diseases. Further, it is likely that some growth factors will be available in bulk quantities, either via direct chemical synthesis or by way of recombinant DNA technology; this will provide an opportunity to test such agents as therapeutic modalities on problems such as nonhealing wounds. When the actions of growth factors in health and disease are precisely defined, genetically engineered competitive inhibitors may offer a wide array of useful therapeutic modalities. 
